Pharmaceuticals

Marina Biotech, Inc. (NASDAQ: MRNA), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 11/955,207 with claims that cover a library of over 1x10(15) novel peptides.

Direxion Daily Emerging Markets Bear 3x Shares(ETF) (NYSE: EDZ) lost 6.11% today, and it closed at $20.12. Banco Bradesco SA (ADR) (NYSE: BBD) is a component of the MSCI Emerging Markets Index, and it gained 2.41%. Direxion Daily Developed Markets Bear 3x Shares(ETF) (NYSE: DPK) fell 5.21%, and...

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has entered into a settlement agreement with Pfizer (NYSE: PFE) which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known generically as Atorvastatin Calcium tablets. The terms of the agreement are...

Shire plc (NASDAQ: SHPGY) today announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme® (imiglucerase...

Bank of America Merrill Lynch is out with its report today on Par Pharmaceutical Companies (NYSE: PRX), raising its PO to $39 from $36. In its report, Bank of America Merrill Lynch writes, "We are raising our DCF-based price objective to $39 (vs. $36), which continues to equate to about 13x our...

Deutsche Bank is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), maintaining Buy. In its report, Deutsche Bank writes, "We maintain our Buy rating. Our 12-month price target remains $57, based on 16x our 2012 Cash EPS estimate of $3.52. We believe the 16x multiple is appropriate...

Bank of America has raised the price objective on Par Pharmaceutical Companies (NYSE: PRX) from $36 to $39 and maintains its Buy rating.

Equity market volatility has increased significantly since I last wrote about a covered call option strategy in July.  Using Born To Sell I have identified some potential covered call opportunities on dividend stocks that have been featured on Scott's Investments within the past month.   If you are...

CNH Global N.V. (NYSE: CNH) +5.47 on heavy volume. NovaGold Resources Inc. (NYSE: NG) +5.45% on rising gold price. Stillwater Mining Company (NYSE: SWC) +5.80% on rising gold price. Jazz Pharmaceuticals (NASDAQ: JAZZ) +6.25% on heavy volume. Lender Processing Services (NYSE: LPS) +6.17% after...

I have published an exclusive article today on Seeking Alpha titled 3 Top Dividend Growth Stocks, which features Novo Nordisk A/S (NVO), Walgreens (WAG), and Murphy Oil (MUR). Click here for a FREE Trading Course Now you can follow me on Stocktwits and Twitter! Disclaimer: No current positions in...

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter Fexofenadine HCl and Pseudoephedrine HCl extended release tablets 180 /240 mg. The Food & Drug Administration approved Dr. Reddy's Abbreviated New Drug Application (ANDA) for Fexofenadine HCl and...

At 9:55 am, the Dow fell 0.78% to 11,449.60, the broader Standard & Poor's 500 index moved down 0.92% to 1,198.90 and the NASDAQ composite index dropped 0.79% to 2,541.98. The industries that are still afloat in the market today are: Nonmetallic Mineral Mining: This industry jumped 1.89% by 9...

Citi is out with its report today on Johnson & Johnson (NYSE: JNJ), maintaining Buy. In its report, Citi writes, "We rate the shares of Johnson & Johnson Buy/Low Risk (1L). While each of JNJ's divisions have dealt with a variety of headwinds heading into 2011, the company has enough...

Citi is out with its report today on Abbott Laboratories (NYSE: ABT), maintaining Sell. In its report, Citi writes, "We rate the shares of Abbott Laboratories Sell/Medium Risk (3M). The recent string of pharmaceutical deals helps Abbott diversify some of the expected generic competition and...

Abbott (NYSE: ABT) today announced the availability of a new molecular test in the European Union and New Zealand designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung cancer.  These rearrangements in a gene known as ALK have been implicated...